Joslin Diabetes Center is the world's largest diabetes research center, diabetes clinic, and provider of diabetes education. It is located in the Longwood Medical and Academic Area in Boston, Massachusetts, United States. Among the Harvard Medical School affiliated institutions, Joslin is unique in its sole focus on diabetes. Joslin has the world's largest team of board-certified physicians treating diabetes and its complications, as well as the largest staff of Certified Diabetes Educators anywhere in the world. Joslin also supports the world's largest diabetes research team with more than 40 faculty investigators and more than 300 researchers. Roberta Herman, M.D., is currently President and CEO of Joslin Diabetes Center. History Joslin Clinic has helped revolutionize the diagnosis, treatment, and prevention of diabetes, most notably by improving the survival rate of babies born to women with diabetes, developing sight-saving laser surgery, devising treatments to reduce amputation, and uncovering ways to predict who will develop diabetes. It was named after Elliott P. Joslin, an American doctor and pioneer in the study of diabetes. Some notable historic milestones include: 1949: Priscilla White, M.D., a founding member of Joslin Clinic, introduces the White Classification of Diabetic Pregnancies. This pioneering concept classifies patients according to their level of risk and tailors their treatment protocol accordingly. When Dr. Priscilla White joined Joslin's practice in 1924, only 56 percent of babies born to diabetic mothers survived; 50 years later when she retired, that rate had jumped to more than 90 percent. 1967: A laser treatment (Ruby laser photocoagulation) is developed by William Beetham, M.D., and Lloyd M. Aiello, M.D., which within the next five years revolutionizes the care of diabetic retinopathy, a potentially blinding complication of diabetes. 1976: Joslin researchers perfect the A1C test, paving the way for this blood test to assess blood glucose control over a two- to three-month period. 1980s: Basic research at Joslin shows that type 1 diabetes evolves over a period of years, presenting hope that a means may be found to prevent autoimmune destruction of the pancreas’ beta cells before they stop producing insulin. 1980s: C. Ronald Kahn and his team defines the molecular mechanism of insulin action and how it is altered in insulin-resistant states such as type 2 diabetes and obesity. 1989: George King, M.D., and colleagues demonstrate that high blood glucose levels activate protein kinase C (PKC), part of a major signaling pathway that causes cellular changes in the